X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MYLAN (US) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   MYLAN
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
MYLAN
Dec-14
GSK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,7604,325-   
Low Rs2,0403,048-   
Sales per share (Unadj.) Rs339.01,480.5-  
Earnings per share (Unadj.) Rs41.4178.3-  
Cash flow per share (Unadj.) Rs45.9287.1-  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.9735.9-  
Shares outstanding (eoy) m84.70378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x7.12.5 284.3%   
Avg P/E ratio x57.920.7 280.4%  
P/CF ratio (eoy) x52.312.8 407.2%  
Price / Book Value ratio x9.95.0 197.3%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,2801,394,690 14.6%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m5,2340-   
Avg. sales/employee Rs ThNM22,406.5-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,699.2-  
INCOME DATA
Net Sales Rs m28,715560,163 5.1%  
Other income Rs m545-3,265 -16.7%   
Total revenues Rs m29,260556,898 5.3%   
Gross profit Rs m5,059139,315 3.6%  
Depreciation Rs m38041,142 0.9%   
Interest Rs m224,162 0.0%   
Profit before tax Rs m5,22270,746 7.4%   
Minority Interest Rs m0-290 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8922,975 63.6%   
Profit after tax Rs m3,50867,481 5.2%  
Gross profit margin %17.624.9 70.8%  
Effective tax rate %36.24.2 861.6%   
Net profit margin %12.212.0 101.4%  
BALANCE SHEET DATA
Current assets Rs m21,815492,457 4.4%   
Current liabilities Rs m15,999385,003 4.2%   
Net working cap to sales %20.319.2 105.6%  
Current ratio x1.41.3 106.6%  
Inventory Days Days6478 81.5%  
Debtors Days Days19107 17.4%  
Net fixed assets Rs m12,475129,592 9.6%   
Share capital Rs m84719,809 4.3%   
"Free" reserves Rs m19,7260-   
Net worth Rs m20,573278,456 7.4%   
Long term debt Rs m6415,986 0.0%   
Total assets Rs m39,4751,121,596 3.5%  
Interest coverage x2,612.03.9 66,498.2%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.70.5 145.6%   
Return on assets %8.98.2 108.8%  
Return on equity %17.124.2 70.4%  
Return on capital %26.213.6 192.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,8650-   
CASH FLOW
From Operations Rs m4,72873,634 6.4%  
From Investments Rs m-1,042-58,070 1.8%  
From Financial Activity Rs m-3,066-19,403 15.8%  
Net Cashflow Rs m620-3,838 -16.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.56 Rs / USD

Compare GSK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: PIRAMAL ENTERPRISES  FULFORD INDIA  CADILA HEALTHCARE  JUBILANT LIFE SCIENCES  STRIDES PHARMA SCIENCE  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views On News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS